You are here: Industry Insights > WuXi AppTec

News List

WuXi STA Completes Acquisition of BMS Manufacturing Facility contractpharma
August 04, 2021
State-of-the-art facility in Couvet, Switzerland enhances WuXi STA's drug product capacity in Europe.
Aptamer and WuXi AppTec Form Research Partnership contractpharma
July 23, 2021
Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, have entered a research collaboration to identify new Optimer-enabled therapeutics.
Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics firstwordpharma
July 23, 2021
Aptamer Group, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
WuXi AppTec Completes OXGENE Acquisition contractpharma
March 03, 2021
WuXi AppTec has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs and develops scalable gene therapy technologies.
WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia prnasia
July 09, 2020
As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases.
WuXi AppTec Appoints Advanced Therapies CEO contractpharma
June 02, 2020
Dr. Chang will provide strategic, scientific and operational leadership to the company's global cell and gene therapy R&D and manufacturing services.
WuXi AppTec Wuhan Site Resumes Operation prnasia
March 12, 2020
WuXi AppTec announced today that the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines.
WuXi AppTec Wuhan Site Resumes Ops contractpharma
March 12, 2020
The Wuhan facility provides discovery chemistry services and will ramp up operations in the coming days and weeks.
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules En-CPhI.CN
October 12, 2019
WuXi AppTec Research Service Division and BioSolveIT launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds ...
WuXi AppTec to expedite early drug discovery biospectrumasia
September 04, 2019
Launches DNA Encoded Library (DEL) Service Package "DELight"

Previous page 1 2 3 Next page